Eyenovia’s (EYEN) “Neutral” Rating Reiterated at HC Wainwright

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $2.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 38.89% from the stock’s current price.

Eyenovia Stock Down 13.8 %

Eyenovia stock opened at $1.44 on Friday. Eyenovia has a 1-year low of $1.31 and a 1-year high of $124.80. The firm has a market capitalization of $2.01 million, a price-to-earnings ratio of -0.02 and a beta of 1.29. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm has a 50 day simple moving average of $2.81 and a 200 day simple moving average of $18.28.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC boosted its holdings in Eyenovia, Inc. (NASDAQ:EYEN) by 36.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 557,994 shares of the company’s stock after buying an additional 149,471 shares during the period. Geode Capital Management LLC owned approximately 0.87% of Eyenovia worth $288,000 as of its most recent filing with the Securities and Exchange Commission. 25.84% of the stock is owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.